The purpose of the study is to see whether the medication can help people reduce or stop drinking. Participants will be randomly assigned to receive either the medication or the placebo for several weeks, during which they will attend regular visits, complete a drinking diary called the Timeline Follow-back (a questionnaire that asks about alcohol use each day), and provide blood samples for a test called Carbohydrate Deficient Transferrin (a lab measure that indicates heavy alcohol consumption). The study also looks at how the drug affects the body’s endocannabinoid system, a natural system that interacts with compounds like cannabidiol, and monitors safety and side effects throughout the trial.

During the trial, participants will receive either CBD oral solution or a placebo. The medication will be taken by mouth for a period of 8 weeks. The maximum daily dose of CBD that participants may receive is 600 mg, while the total maximum dose throughout the study period is 33,600 mg.

The study will evaluate how CBD affects drinking behavior and measure certain biological markers in the blood that indicate alcohol use. The research will also assess how well participants tolerate the medication and examine its overall safety for people with alcohol dependence. Additionally, the study will look at psychological aspects related to alcohol consumption and investigate how CBD interacts with the body’s natural endocannabinoid system.

The purpose of the study is to assess how effective the combination of 800mg or 1200mg of oral CBD with 50mg of oral Naltrexone is in reducing alcohol cravings compared to a placebo. Participants will take part in a series of visits over a period of time, where they will receive either the active treatment or a placebo. The study will monitor changes in alcohol craving levels, quality of life, and other related symptoms throughout the trial.

Participants will be asked to attend several visits, where they will undergo assessments to measure their alcohol cravings and other health indicators. The study will also track changes in mood, anxiety, and overall well-being. This research aims to provide insights into how Cannabidiol and Naltrexone can work together to help individuals manage their alcohol dependence more effectively.

The purpose of the study is to evaluate the potential of cannabidiol in helping individuals with alcohol dependence reduce their alcohol consumption and achieve abstinence. The study will monitor changes in alcohol consumption and certain markers in the blood that indicate alcohol use. Participants will be involved in the study for a period of up to eight weeks, during which they will take the oral solution and attend regular check-ups to assess their progress and any effects of the treatment.

Throughout the study, researchers will also assess the safety and tolerability of cannabidiol in individuals with alcohol dependence. This will help determine if cannabidiol can be a safe and effective option for managing alcohol dependence and reducing the psychological symptoms associated with alcohol use. The study aims to provide valuable insights into the role of the endocannabinoid system, which is involved in regulating various bodily functions, in alcohol dependence.

The purpose of the study is to see how effective and safe psilocybin-assisted therapy is in helping people reduce their alcohol consumption. Participants will be monitored for changes in their drinking habits from before they start the program until four weeks after they leave the hospital. The study will also look at how easy it is to recruit and keep participants in the program, as well as any safety concerns that may arise.

Throughout the study, participants will receive therapy sessions to help them prepare for and integrate the experience of taking psilocybin. The study will also explore various psychological and cognitive aspects, such as changes in mood, anxiety, and the ability to cope with cravings. The goal is to better understand how psilocybin, combined with therapy, can support recovery from alcohol use disorder.